Pluristem Therapeutics  logo
Pluristem Therapeutics PSTI
report update icon

Quarterly report 2027-Q1
added 11-12-2026

Pluristem Therapeutics Net Income | PSTI

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Pluristem Therapeutics

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
-23.8 M -22.6 M 21.3 M 28.9 M -41.2 M -49.9 M -29.2 M -35.3 M -26.1 M -27.8 M -23.2 M -24.7 M -26.9 M -21.2 M -14.8 M -10.8 M -2.82 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
28.9 M -49.9 M -19.4 M

Quarterly Net Income Pluristem Therapeutics

2027-Q1 2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
11.5 B 412 M 10.1 B 9 B 7.99 B 479 M 6.56 B 5.55 B 5.45 B 5.25 B -5.39 M -4.99 M -5.1 M 51.2 M -7.76 M -8.25 M -6.27 M -8.12 M -6.12 M -14.2 M -11.4 M -10.9 M -11.4 M -22.4 M -8.49 M -12.6 M -7.51 M -6.37 M -8.49 M -7.76 M -10.1 M -6.37 M -7.14 M -8.98 M -1.53 M -8.68 M -8.79 M -8.23 M -7.38 M -8.23 M -7.38 M -6.2 M -7.2 M -3.96 M -5.88 M -5.3 M -7.23 M -6.24 M -5.91 M -6.2 M -9.28 M -6.7 M -4.76 M -6.7 M -4.76 M -4.49 M -4 M -4.14 M -4 M -4.49 K -4 M -1.99 K -4.49 M -1.99 M -4.49 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
11.5 B -22.4 M 953 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
IMARA IMARA
IMRA
-104 M - 15.96 % $ 663 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
-110 M - - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
83.2 M - -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
-56 M - - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
-6.08 M - - $ 63.4 M usaUSA
Magenta Therapeutics Magenta Therapeutics
MGTA
-162 M - -7.74 % $ 41.6 M usaUSA
NovaBay Pharmaceuticals NovaBay Pharmaceuticals
NBY
-631 M - - $ 11.3 M usaUSA
NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals
NRBO
-13 M - 0.43 % $ 12 M usaUSA
OncoCyte Corporation OncoCyte Corporation
OCX
-50.2 K - 17.22 % $ 355 K usaUSA
Onconova Therapeutics Onconova Therapeutics
ONTX
9.17 M - -0.47 % $ 21 M usaUSA
Opthea Limited Opthea Limited
OPT
-163 M - - $ 1.2 B australiaAustralia
Verastem Verastem
VSTM
-209 M $ 6.33 -7.8 % $ 439 M usaUSA
BiomX BiomX
PHGE
-36.2 M $ 1.85 14.2 % $ 3.02 M israelIsrael
Pieris Pharmaceuticals Pieris Pharmaceuticals
PIRS
-41.7 M - -15.58 % $ 1.22 B germanyGermany
Plus Therapeutics Plus Therapeutics
PSTV
-22.4 M - - $ 301 M usaUSA
Qualigen Therapeutics Qualigen Therapeutics
QLGN
-17 M - 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
-19.9 M - -6.08 % $ 184 M chinaChina
Cassava Sciences Cassava Sciences
SAVA
-91 M - - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
-130 M - -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
-123 M - - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
-12.5 M - - $ 2.64 M usaUSA
Sensei Biotherapeutics Sensei Biotherapeutics
SNSE
-21.1 M - - $ 17.5 M usaUSA
Sonnet BioTherapeutics Holdings Sonnet BioTherapeutics Holdings
SONN
-16 M - - $ 826 K usaUSA
Synthetic Biologics Synthetic Biologics
SYN
-23.7 M - 1.32 % $ 16.2 M usaUSA
Synlogic Synlogic
SYBX
-1 M - - $ 7.07 M usaUSA
Virios Therapeutics, LLC Virios Therapeutics, LLC
VIRI
-34.3 M - 2710.01 % $ 72.9 M usaUSA
Vallon Pharmaceuticals Vallon Pharmaceuticals
VLON
-12 M - -6.47 % $ 5.76 M usaUSA
Vaxart Vaxart
VXRT
5.18 M - -25.06 % $ 46.3 M usaUSA
XOMA Corporation XOMA Corporation
XOMA
31.7 M - - $ 485 M usaUSA
Repare Therapeutics Repare Therapeutics
RPTX
-84.7 M - - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
-60.5 M - 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
-1.79 M - - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
-66 M - - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
-79.5 M - 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
-71.2 M - 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
-8.38 M - - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
72.9 M - - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
-28.9 M - - $ 24.9 M usaUSA
Brickell Biotech Brickell Biotech
BBI
-5.69 M - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-106 M - - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
-28.5 M - - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
-132 M - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
-34.4 M - - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
-215 M - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
-130 M - - $ 2.36 B usaUSA
Annexon Annexon
ANNX
-207 M $ 3.11 -8.94 % $ 482 M usaUSA